Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis

BACKGROUND: Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy (nICT) or chemoradiotherapy (nICRT) has been tested in resectable esophageal cancer. Nevertheless, efficacy and safety for this new strategy have not been clearly demonstrated. PATIENTS AND METHODS: PubMed, Embase,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, He, Li, Sihan, Liu, Tingting, Chen, Jun, Dang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513123/
https://www.ncbi.nlm.nih.gov/pubmed/36177019
http://dx.doi.org/10.3389/fimmu.2022.998620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513123/
https://www.ncbi.nlm.nih.gov/pubmed/36177019
http://dx.doi.org/10.3389/fimmu.2022.998620

Ejemplares similares